SRNE

Sorrento Therapeutics, Inc. SRNE

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode SRNE ENSC DOSEF RPNRF FAMDF ENZN CLABF TXTM FNAM KNBIF
6M -54.55 % -49.55 % -90.43 % 0.00 % -76.92 % -50.24 % -99.98 % -7.69 % 0.00 % -24.00 %
YTD 25.00 % -86.55 % -63.27 % 0.00 % -92.50 % -76.56 % -99.98 % 260.00 % -75.00 % -65.45 %
1Y 42.86 % -88.88 % -63.27 % 0.00 % -92.11 % -80.82 % -99.99 % 227.27 % -75.00 % -60.50 %
3Y -86.51 % -99.15 % -77.07 % 100.00 % -94.23 % -83.45 % -100.00 % 38.46 % -99.97 % -55.67 %
5Y -98.73 % -100.00 % -92.63 % -93.33 % -84.21 % -82.94 % -100.00 % 620.00 % -99.98 % -75.82 %
10Y -98.94 % -100.00 % -92.63 % -80.00 % -92.11 % -95.06 % -100.00 % 3 500.00 % -99.99 % -83.88 %
From the beginning -98.84 % -100.00 % -92.63 % -80.00 % -98.01 % -96.94 % -100.00 % -99.99 % -100.00 % -98.61 %

Dividend

Enzon Pharmaceuticals, Inc.